Skip to content
naulon
Not checkedNot checked for notices yet.

From design to clinic: Engineered peptide nanomaterials for cancer immunotherapy

Jing-Jing Du, Zhenhong Su, Haoyi Yu and 3 more

Frontiers in Chemistry · 2023

doi:10.3389/fchem.2022.1107600 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Immunotherapy has revolutionized the field of cancer therapy. Nanomaterials can further improve the efficacy and safety of immunotherapy because of their tunability and multifunctionality. Owing to their natural biocompatibility, diverse designs, and dynamic self-assembly, peptide-based nanomaterials hold great potential as immunotherapeutic agents for many malignant cancers, with good immune response and safety. Over the past several decades, peptides have been developed as tumor antigens, effective antigen delivery carriers, and self-assembling adjuvants for cancer immunotherapy. In this review, we give a brief introduction to the use of peptide-based nanomaterials for cancer immunotherapy as antigens, carriers, and adjuvants, and to their current clinical applications. Overall, this review can facilitate further understanding of peptide-based nanomaterials for cancer immunotherapy and may pave the way for designing safe and efficient methods for future vaccines or immunotherapies.

Abstract licence: CC BY

References102

  1. 20.

39 more references, whose wording the paper’s licence keeps private.

All 102 references

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.